Skip to main content
. 2019 Sep 30;12:8003–8014. doi: 10.2147/OTT.S155778

Figure 1.

Figure 1

Comparison of acalabrutinib, ibrutinib, and spebrutinib in competitive binding assays on wild-type and mutant kinases (DiscoverX).56